ZORYL MP 2 FORTE

Distributor inventory

Type 2 diabetes mellitus (when diet and exercise alone or single/dual therapy is inadequate), to improve glycaemic control

Glimepiride (sulfonylurea) increases insulin release from pancreatic beta cells. Metformin reduces hepatic glucose production and improves peripheral insulin sensitivity. Pioglitazone (PPAR-γ agonist) improves insulin sensitivity in muscle and adipose tissue, helping reduce insulin resistance.

Oral tablet. Take exactly as prescribed, usually once daily with/after the first main meal to reduce stomach upset and risk of low sugar. Swallow whole (do not crush/chew if modified-release). Monitor blood glucose regularly and follow diet/exercise advice.

Hypoglycaemia, nausea, diarrhoea, abdominal discomfort, headache, dizziness, weight gain, oedema (swelling), upper respiratory tract infection

Risk of hypoglycaemia (higher with missed meals, alcohol, strenuous exercise, elderly, renal/hepatic impairment). Metformin: rare risk of lactic acidosis—avoid in severe kidney impairment, dehydration, severe infection, hypoxia; temporarily stop before/after iodinated contrast or major surgery as advised. Pioglitazone: can cause fluid retention/heart failure worsening—avoid in NYHA class III/IV heart failure; monitor for oedema and weight gain. Long-term metformin may reduce vitamin B12—consider periodic monitoring. Use caution in liver disease; monitor liver enzymes. Not for type 1 diabetes or diabetic ketoacidosis.